TC BioPharm Announces $7.35 Million Private Placement
TC BioPharm (Nasdaq: TCBP) announced a private placement agreement for 1,470,000 American Depositary Shares (ADSs) and associated warrants, raising an expected $7.35 million. The purchase price is set at $5.00 per ADS, with Series A and B warrants exercisable at the same price. The closing is anticipated on November 30, 2022, subject to customary conditions. Proceeds will support general working capital. The offering is exclusively for accredited investors under Section 4(a)(2) of the Securities Act, and the Company plans to file registration statements with the SEC for resale of the ADSs.
- Successful private placement raising $7.35 million.
- Immediate exercise of warrants may provide additional capital.
- Continued focus on development of gamma-delta T cell therapies.
- Additional dilution for existing shareholders due to new ADS issuance.
- Reliance on private placement may indicate challenges in accessing broader capital markets.
EDINBURGH, Scotland, Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that it has entered into a securities purchase agreement with healthcare-focused and institutional investors for the sale and issuance in a private placement of 1,470,000 American Depositary Shares (the "ADSs")(or ADS equivalents in lieu thereof), Series A warrants to purchase up to an aggregate of 1,470,000 ADSs and Series B warrants to purchase up to an aggregate of 1,470,000 ADSs at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The closing of the private placement is expected to occur on or about November 30, 2022, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the private placement is expected to be
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the ADSs and ADSs issuable upon exercise of warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and include statements regarding the consummation of the private placement; the use of the net proceeds therefrom; the filing of a registration statement by TC BioPharm with the SEC covering the resale of the securities to be issued in the private placement. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release, such as market and other conditions. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
View original content:https://www.prnewswire.com/news-releases/tc-biopharm-announces-7-35-million-private-placement-301687527.html
SOURCE TC BioPharm
FAQ
What is the total amount raised in the TC BioPharm private placement?
When is the closing date for TC BioPharm's private placement?
What is the exercise price of the warrants issued by TC BioPharm?
Who acted as the placement agent for TC BioPharm's offering?
What will TC BioPharm use the proceeds from the private placement for?
